This program, titled "Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan," aligns with the country’s national health
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
Nadda also commended the role of ASHA workers, “grassroot foot soldiers”, in the healthcare system
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The scheme is fully digitized and covers approximately 45% of India's population
Subscribe To Our Newsletter & Stay Updated
